Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study

NCT06785584 is registered in ClinicalTrials.gov with Fujian Medical University Union Hospital as lead sponsor.

NCT NCT06785584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06785584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study
Lead sponsor
Fujian Medical University Union Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
February 1, 2025
Completion date
December 1, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive advanced nsclc, alk-positive non-small cell lung cancer (nsclc), mpr, neoadjuvant therapy